Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model
Portfolio Pulse from
Ascletis announced that its drug candidate ASC47, when combined with semaglutide, showed superior weight loss in a preclinical model compared to semaglutide alone. The combination resulted in a 56.7% greater reduction in body weight.

December 18, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Novo Nordisk's semaglutide, a key component in the study, was outperformed by the combination with Ascletis' ASC47 in preclinical trials, showing a 56.7% greater weight loss.
The study results suggest that the combination of ASC47 with semaglutide is more effective than semaglutide alone, potentially impacting Novo Nordisk's market position for obesity treatments.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80